Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Haemophilia and ageing.

Haemophilia : the official journal of the World Federation of Hemophilia·2006
Same author

The 2002/3 Canadian Cardiovascular Society consensus guideline update for the diagnosis and management of heart failure.

The Canadian journal of cardiology·2003
Same author

The 2001 Canadian Cardiovascular Society consensus guideline update for the management and prevention of heart failure.

The Canadian journal of cardiology·2002
Same author

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Circulation·2001
Same author

Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.

European heart journal·2000
Same author

Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial.

Circulation·1997

相关实验视频

Updated: Jul 3, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

在胆固醇和复发事件 (CARE) 试验中,VLDL,阿波利波蛋白B,CIII和E以及复发性冠状动脉事件的风险.

F M Sacks1, P Alaupovic, L A Moye

  • 1Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA. fsacks@hsph.harvard.edu

Circulation
|October 18, 2000
PubMed
概括
此摘要是机器生成的。

在VLDL和LDL中的VLDL颗粒和apoCIII比血甘油三素更好地预测冠状动脉疾病风险. 这些措施与动脉样硬化更密切相关,改善了对心血管事件的风险评估.

更多相关视频

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

相关实验视频

Last Updated: Jul 3, 2026

Cholesterol Efflux Assay
07:54

Cholesterol Efflux Assay

Published on: March 6, 2012

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

科学领域:

  • 心血管医学 心血管医学
  • 脂质代谢 脂质代谢是什么
  • 动脉样硬化研究 动脉样硬化研究

背景情况:

  • 血甘油三水平与冠心病 (CHD) 风险存在不一致的关联.
  • 这种不一致性可能源于VLDL颗粒的代谢异质性,VLDL颗粒是主要的甘油三载体.

研究的目的:

  • 调查VLDL颗粒度和特定的阿波利波蛋白 (apoCIII,apoE) 是否比血甘油三素更准确地预测心脏病风险.
  • 确定VLDL-apolipoprotein B (apoB),apoCIII和apoE与心血管事件有关的独立预测值.

主要方法:

  • 在胆固醇和复发性事件 (CARE) 试验中进行的一项前性,嵌套的病例对照研究.
  • 在5年内,在患有 (病例) 和没有 (对照) 心血管事件的患者之间,在VLDL+LDL和HDL中比较VLDL颗粒 (VLDL-apoB),VLDL脂质,apoCIII和apoE的基线度.
  • 利用后勤回归来识别冠状动脉事件的独立预测因子,调整传统的脂质测量.

主要成果:

  • 在VLDL中,VLDL胆固醇,VLDL甘油三,VLDLapoB,VLDL+LDL中的apoCIII和HDL中的apoE都是冠状动脉事件的相互关联和无变的预测因素.
  • VLDL-apoB (RR 3.2),VLDL+LDL中的apoCIII (RR 2.3) 和HDL中的apoE (RR 1.8) 是随后冠状动脉事件的显著独立预测因素.
  • 当VLDL+LDL中的apoCIII被纳入模型时,血甘油三并不是显著的预测因子,这突显了apoCIII的独立作用.

结论:

  • 在VLDL和LDL中的VLDL颗粒和apoCIII的血度是冠状动脉疾病风险的更具体的指标,而不是血甘油三.
  • 这些特定的VLDL成分可能是优越的风险标志物,因为它们与动脉样硬化过程的更密切的代谢联系.